Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Ophthalmologists

Articles with lock require a subscription to GLG News | Request a free trial
August 31, 2007
LX211 (LUX) could be a Blockbuster Drug in the Treatment of Uveitis.
Analysis of: Lux granted fast track designation by FDA for LX211 for the treatment of uveitis | www.pipelinereview.com
Author: GLG Expert Contributor
LX211, calcineurin inhibitor and antiinflammatory drug, was granted Fast Track designation by the FDA.  This move could expedite its approval for the management of non-infectious posterior, intermediate and panuveitis.  In a field where there are few approved treatment modalities, this could...
Mark PackerAugust 30, 2007
Eyeonics Going Public
Analysis of: Eyeonics Files For IPO | www.socaltech.com
Author: Mark Packer, Clinical Associate Professor of Ophthalmology, OREGON HEALTH & SCIENCE UNIVERSITY - CC
Rather than getting gobbled up by one of the big three players in Ophthalmology (B & L, Alcon and AMO), eyeonics is looking to go it alone into the public arena.  The crystalens remains the only approved accommodative intraocular lens, but faces strong competition from the multifocals. ...
August 27, 2007
The New Medicare Regulations: Realistic or The Beginning of a Witch Hunt
Analysis of: New Medicare Regulations Adopted To Reduce Certain Hospital Infections And Medical Errors | www.medicalnewstoday.com
Author: Abdhish Bhavsar, Owner, Abdhish Bhavsar, MD
The new Medicare regulations are not based in science as there is no proven clear cut medical way to eliminate the incidence of these "so-called" medical errors. It would be a dream to believe that some intervention today can eliminate the occurrence of infections in hospitals or patient falls. ...
August 13, 2007
TEARS OF THE RETINAL PIGMENT EPITHELIUM: An Old Problem in a New Era.
Analysis of: Tears in the Retinal Pigment Epithelium: A Complication Associated with the New Macular Degeneration Treatments | pt.wkhealth.com
Author: GLG Expert Contributor
Tears of the retinal pigment epithelium (RPE) may develop during the course of anti-VEGF therapy for age-related macular degeneration (AMD) related pigment epithelial detachment (PED), according to a study published in the June issue of Retina.  A total of 33 cases of RPE tear after treatment with...
August 13, 2007
Bimatoprost (AGN) may have better Pressure Control but Latanoprost (PFE) is still KING.
Analysis of: Bimatoprost May Provide Better Intraocular Pressure Control Than Latanoprost | www.medscape.com
Author: GLG Expert Contributor
This glaucoma drug efficacy crossover study shows that bimatoprost (Lumigan) from AGN lowers intraocular pressure better than latanoprost (Xalatan) from PFE in a special subset of glaucoma patients (exfoliative glaucoma).  The difference is only 1 mm Hg which may be statistically significant will...
August 13, 2007
Eyelid basal cell carcinoma
Analysis of: Basal Cell Carcinoma of the Eyelids | www.medscape.com
Author: GLG Expert Contributor
1. Eyelid basal cell carcinoma. 2. Health problem. 3. Early diagnostic and correct surgery treatment. 4. Risk factors and prevention.
August 10, 2007
Bimatoprost is known to be slighatly more potent that prostaglandin
Analysis of: Bimatoprost May Provide Better Intraocular Pressure Control Than Latanoprost | www.medscape.com
Author: GLG Expert Contributor
1. Exfoliative glaucoma is specillay difficult to treat medically. 2. Prostaglandin. 3. Early surgery. 4. Lesser costs.
August 9, 2007
VEGF Trap (RGN, BAY) may give Lucentis (DNA) some competition in the AMD Market.
Analysis of: Bayer HealthCare and Regeneron initiate Phase 3 global development program for VEGF Trap-Eye in wet age-related macular degeneration (AMD) | www.pipelinereview.com
Author: GLG Expert Contributor
Bayer and Regeneron are moving forward with their Phase 3 Trial called the VIEW involving VEGF Trap for the treatment for choroidal neovascularization in Age Related Macular Degeneration.  The implications are large for a billion dollar market that is currently dominated by Lucentis (DNA).
August 2, 2007
AMO takeover of B&L
Analysis of: AMO outbids private equity firm for Bausch & Lomb | www.osnsupersite.com
Author: GLG Expert Contributor
Bad news merger of AMO and B&L..
July 30, 2007
High Density Silicone Oil may be Useful in Complex Retinal Surgery.
Analysis of: High-Density Silicone Oil Useful Retinal Tamponade | www.medscape.com
Author: GLG Expert Contributor
This uncontrolled pilot study in 12 eyes reports that that high density silicone oil was successful in the treatment of a complex retinal disease problem, a macular hole with a central retinal detachment in myopic patients.  Although this work is exciting for this particular condition, its applications...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Next61 to 70 of 158

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T21:45:56.203